Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Limited (NASDAQ: ZURA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
Zura Bio Limited (NASDAQ: ZURA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.